Ardelyx Earnings Call: IBSRELA Fuels Growth Story
Ardelyx Inc ((ARDX)) has held its Q4 earnings call. Read on for the main highlights of the call.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Ardelyx’s latest earnings call struck a tone of confident growth tempered by visible risks. Management highlighted explosive momentum for IBSRELA and a stronger pipeline, while acknowledging the drag from Medicare-driven XPHOZAH declines and sharply higher operating costs. Investors are being asked to accept near‑term losses in exchange for outsized future revenue.
IBSRELA Delivers Breakout Growth and Ambitious Targets
IBSRELA remained the clear growth engine, with 2025 net revenue reaching $274.2 million, up 73% from 2024 and Q4 revenue up 61% year over year. Management guided 2026 IBSRELA revenue to $410–$430 million, implying at least 50% growth, and reiterated its goal to scale the brand to $1 billion in annual sales by 2029.
Balanced Revenue Growth and Strengthening Cash Position
Total company revenue rose 22% in 2025 to $407.3 million, driven primarily by IBSRELA and partially offset by XPHOZAH’s decline. Ardelyx ended the year with $264.7 million in cash, cash equivalents and short‑term investments and reported two straight quarters of positive cash flow, giving it more flexibility to fund growth.
Commercial Execution Underpins Market Momentum
Management pointed to record highs across key commercial metrics for IBSRELA in 2025 and ongoing quarter‑over‑quarter growth for both products. To extend this momentum, the company is investing in broader prescriber reach, doubling its field reimbursement manager team and building out a specialty pharmacy network to boost prescription pull‑through.
XPHOZAH Sees Mixed Picture Beyond Medicare Headwinds
While XPHOZAH’s overall dispenses rose 9% in 2025, paid dispenses excluding Medicare jumped 41%, underscoring strong demand where coverage exists. Ardelyx expects XPHOZAH to generate $110–$120 million in 2026 and still sees a long‑term peak opportunity of $750 million ahead of its patent expiry.
ACCEL Phase III CIC Trial Expands Tenapanor Franchise
The company launched the ACCEL Phase III study of tenapanor in chronic idiopathic constipation, dosing the first patient and targeting about 700 participants across roughly 110 U.S. sites. The trial is powered on a durable CSBM endpoint at week 12, with full enrollment expected by year‑end and topline data planned for the second half of next year.
Next‑Generation NHE3 Candidate Positions Future Pipeline
Ardelyx is advancing its next‑generation NHE3 inhibitor, RDX‑10531, which has shown roughly ten‑fold higher potency and about thirty‑fold greater solubility than tenapanor in preclinical work. These attributes could enable once‑daily dosing, and the company aims to file an IND in the second half of this year before starting a Phase I trial.
New Orange Book Patent Extends Formulation Protection
The company’s intellectual property position improved with a new formulation patent for IBSRELA and XPHOZAH listed in the FDA’s Orange Book. This patent runs through 2042, extending protection well beyond the core composition‑of‑matter patent and potentially helping defend branded pricing and market share.
Medicare Policy Change Hammers XPHOZAH Revenue
Despite volume gains outside Medicare, XPHOZAH revenue dropped to $103.6 million in 2025 from $160.9 million in 2024, a 36% decline. The chief culprit was the loss of Medicare Part D reimbursement at the start of 2025, removing coverage for a segment that previously represented about 60% of the product’s patient base.
Net Loss Widens as Operating Expenses Climb
Ardelyx’s net loss widened to $61.6 million, or $0.26 per share, in 2025 versus $39.1 million, or $0.17 per share, the prior year. Management signaled that spending will keep rising, with 2026 operating expenses expected to increase around 25% to as much as $520 million to support commercialization and development.
R&D and SG&A Surge to Fund Growth Agenda
Research and development expenses climbed to $71.5 million in 2025 from $52.3 million as the pipeline advanced and new trials started. Selling, general and administrative costs increased to $337.2 million from $258.7 million, reflecting heavier investment in sales infrastructure, market access and promotional efforts for both brands.
Execution Risk Around Pull‑Through and Specialty Pharmacy
Management’s 2026 outlook relies heavily on making prescriptions convert more consistently into paid dispenses through a larger reimbursement team and a specialty pharmacy network. While this strategy could enhance revenue efficiency, it introduces execution risk if operational gains in pull‑through fall short of internal expectations.
Patent Timelines Highlight Longer‑Term Generic Overhang
The core composition‑of‑matter patent for tenapanor expires in 2033, opening the door to potential generic competition later in the decade. Although the new 2042 formulation patent and other IP help extend protection, investors will eventually need to weigh how Ardelyx defends share and pricing once originator patents roll off.
Guidance Points to Aggressive Growth and Higher Spend
For 2026, Ardelyx guided IBSRELA revenue to $410–$430 million and XPHOZAH to $110–$120 million while reaffirming a $1 billion IBSRELA target in 2029 and a $750 million XPHOZAH peak opportunity. The company expects similar gross‑to‑net dynamics, first‑quarter phasing comparable to 2025 and roughly 25% higher operating expenses, including stepped‑up R&D and SG&A.
Ardelyx’s earnings call laid out a classic high‑growth, high‑investment story, with IBSRELA’s trajectory and pipeline progress offset by XPHOZAH reimbursement pressure and mounting losses. For investors, the key questions will be whether the company can execute on pull‑through, manage costs and deliver on its bold revenue milestones before generic risks emerge.
